Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04996914 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma

Study acronym: ASTrH
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 5 more changesShow less
    • Primary completion date: Aug 1, 2027 to May 5, 2028
    • Start date changed from estimate of Sep 1, 2025 to May 5, 2026
    • Study sites: 0 to 1
    • Study completion date: Aug 1, 2028 to May 5, 2029
    • Secondary endpoints: 3 to 5
  2. Primary completion date: Jan 1, 2024 to Aug 1, 2027
    • Start date: Jan 1, 2022 to Sep 1, 2025
    • Study completion date: Jan 1, 2025 to Aug 1, 2028
    • Eligibility criteria shortened, about 3 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC not amenable for surgical resection.
Trial Details
NCT Number NCT04996914
Lead Sponsor RWTH Aachen University
Conditions
(from sponsor)		 Hepatocellular Carcinoma Non-resectable
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov